in EGFR- mutation-positive non-small-cell lung cancer after progression on first-line gefitinib
Soria, J.C., et al., Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR- mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria, J .C ., et al ., Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR- mutation-positive non-small-cell lung cancer after progression on first-line gefitinib ( IMPRESS ) : a phase 3 randomised trial .